GRACE :: Lung Cancer
GRACE Video

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share
 
The videos below were filmed at the October 2015 Acquired Resistance for ALK, ROS1, & EGFR Lung Cancer Patient Forum. Please note that the information presented in the videos was accurate in October 2015. Progress in treatments for patients with ALK, ROS1 and EGFR lung cancer changes rapidly. If you have questions about the information in these videos, please post them in the GRACE forum.
 

AR_2015_Reckamp_Acquired_Resistance_Defining_What_Why
What is Acquired Resistance to Targeted Therapy, and Why Does it Occur?
26:54
 
Dr. Karen Reckamp of City of Hope Cancer Center reviews the concept of acquired resistance to targeted therapies in patients with a driver mutation and why it occurs.
 
AR_2015_CNS_Sanctuary_Site_Special_Case_Brain_Metastases
The Central Nervous System as a Sanctuary Site: The Special Case for Brain Metastases
23:54
 
Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in patients with NSCLC and a driver mutation.
 
AR_2015_QA_Reckamp_Owonikoko_Acquired_Resistance
Panel Q&A Session on Acquired Resistance with Drs. Reckamp & Owonikoko
36:39
 
Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.
 
AR_2015_Horn_Liquid_Biopsies_Acquired_Resistance_Mutations
Repeat Biopsies and Emerging Technologies for Plasma Sampling of Mutations Seen with Acquired Resistance
21:18
 
Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling as a “liquid biopsy” option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.
 
AR_2015_Riely_Immunotherapy_Driver_Mutation_Advanced_NSCLC
What is the Role of Immunotherapy for Patients with Advanced NSCLC and a Driver Mutation?
20:04
 
Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.
 
AR_2015_QA_Riely_Horn_Acquired_Resistance
Panel Q&A Session on Acquired Resistance with Drs. Riely & Horn
19:30
 
Dr. West moderates a question & answer session with Drs. Leora Horn and Greg Riely on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.
 
AR_2015_Owonikoko_New_Ideas_Treatment_Options_ALK_ROS1
New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1
31:42
 
Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.
 
AR_2015_Horn_Blood_Brain_Barrier_ALK
The Blood/Brain Barrier for ALK Patients
14:15
 
The brain is a common site of disease in patients with ALK+ lung cancer. In this video, Dr. Horn illustrates the line-up of ALK+ treatments and how they work breaking through the blood/brain barrier.
 
AR_2015_QA_Horn_Freeman_Owonikoko_ALK_ROS1
Panel Q&A Session on ALK+ and ROS1 Acquired Resistance with Drs. Horn and Owonikoko
28:14
 
Janet Daily-Freeman moderates a question & answer session with Drs. Leora Horn and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for ALK+ and ROS1 patients.
  
AR_2015_West_Treatments_Specific_EGFR_Mutations
Individual Treatments for Individual EGFR Mutations
17:44

 
There are sub-types within the sub-type of EGFR mutation positive lung cancer. In this presentation, Dr. Jack West discusses the different activating mutations within EGFR positive tumors and how they impact treatment.
 
AR_2015_Riely_T790M_Positive_Acquired_Resistance_Options
Emerging Options for T790M-Positive Acquired Resistance
13:53
 
Acquired resistance in EGFR patients is often driven by the T790M mutation. T790M-positive tumors respond differently to treatments than T790M-negative tumors. Dr. Greg Riely details how each status can predict patients’ responses to current treatments.
 
AR_2015_West_EGFR_T790M_Negative_Acquired_Resistance_Options
Treatment Options for EGFR T790M Negative Acquired Resistance
24:36
 
Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.
 
AR_2015_QA_West_Riely_Sequencing_Older_Newer_EGFR_Agents
Panel Q&A Session on Sequencing EGFR Treatments with Drs. Riely and West
26:34
 
Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.
 
AR_2015_Bietry_Access_Assistance_ALK_ROS1_EGFR
Access & Assistance for ALK+, ROS1 & EGFR Patients
14:18
 
Brendan Bietry of the Patient Advocate Foundation discusses the financial assistance programs available to lung cancer patients who receive targeted therapies.
 
AR_2015_Freeman_Living_With_Lung_Cancer_Survivorship
Living with Lung Cancer
12:21
 
Janet Freeman-Daily, a ROS1 lung cancer patient since 2011, talks about the importance of patients’ involvement in their own health care and the support that exists online to help patients navigate the system.
 
AR_2015_QA_Bietry_West_Freeman_Patient_Access_Survivorship
Panel Q&A Session on Patient Access and Survivorship
15:15
 
Dr. Jack West, Brendan Bietry, and Janet Freeman-Daily take questions from the audience about financial assistance, legal protections, and patient support.

Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243